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Abstract
Background: Although worry about recurrence is a persistent concern among breast cancer survivors,
little is known about physicians’ conﬁdence about presenting recurrence risk information, identifying
women with considerable worry, and helping women manage worry.
Methods: Between January and June 2012, we surveyed 750 surgeons and 750 medical oncologists
randomly sampled from the American Medical Association Physician Masterﬁle. We tested differences
between surgeons and medical oncologists on conﬁdence of presenting risk, identifying and managing
worry using chi-square statistic and Student’s t-tests and developed multiple variable logistic regression
models to explain odds regarding conﬁdence and use of different strategies for managing worry.
Results: The analytic sample included 403 surgeons and 363 medical oncologists (n=766; response
rate = 60%). Compared with surgeons, medical oncologists were signiﬁcantly more likely to report conﬁ-
dence in: presenting risk information (87.5% vs 73.2%), identifying women who are worried (74.1% vs
63.9%), and managing worry (66.9% vs 52.4%). Conﬁdence in managing worry was associated with
more regular inquiry about worry (p=0.009). Models of the likelihood of using different management
strategies varied by provider type (e.g., surgeons more likely than medical oncologists to recommend
support group or online resources, oncologists more likely to refer to psychologist or use medications,
all p< 0.05).
Conclusion: Cancer providers, particularly surgeons, may beneﬁt from educational training to raise
conﬁdence in identifying women with high levels of worry and managing women with considerable
worry. Communication between specialties and primary care physicians on efforts to manage worry
is necessary for coordinated, quality care for women with breast cancer.
Copyright © 2014 John Wiley & Sons, Ltd.
Introduction
Considerable research has documented that worry about
recurrence is a major concern among women with breast
cancer in the survivorship period [1–7]. A recent review
of studies of long-term cancer survivors concluded that
modestly intense fear of recurrence is experienced by most
long-term survivors [8]. Most studies to date have focused
on the patients’ perceptions about recurrence risk and the
potential negative consequences of excessive worry on
decision-making, surveillance behaviors and quality of
life [9–12], with signiﬁcant negative associations between
considerable worry, and psychological distress and quality
of life [7]. Far less attention has been focused on how
conﬁdent providers of cancer care are at presenting risk
information, identifying women with considerable worry,
and assisting women to manage worry about recurrence
over time.
The Institute of Medicine has stated that psychosocial
care is integral to quality survivorship care [13]. Indeed,
studies that have focused on provider perceptions gener-
ally ﬁnd that physicians caring for women with breast
cancer consider addressing psychosocial concerns to be part
of their responsibility [14–17]. Some attention has been
devoted to developing online tools and other resources to
assist physicians in presenting risk information to their
breast cancer patients [18–22], although most communi-
cations of recurrence risk have focused on improving
treatment decision-making more than clarifying risk of
recurrence itself.
In order to address the psychosocial needs of cancer
survivors, physicians need to routinely assess mental
health concerns of their patients and refer to appropriate
mental health professionals as needed. Cancer survivors
whose mental health concerns are addressed report greater
satisfaction with the quality of their care [23]. Previous
Copyright © 2014 John Wiley & Sons, Ltd.
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studies have suggested that physicians tend to underesti-
mate the level of depressive symptoms in patients and
may be unaware of the importance of assessing the more
reliable symptoms of mental health distress [24–26].
Despite the demonstrated need for mental health support,
a recent population-based survey found that less than half
of the cancer survivors reported that they discussed the
psychological effects of cancer with their physician and/
or were referred to mental health specialists or support
groups [23].
In addition to identifying women with elevated levels of
worry about recurrence, better strategies to help these
women manage their worry are also needed. A variety of
approaches or strategies are available to help women
manage worry ranging from information sources in print
or online formats, support groups or peer counseling,
referrals to other professionals, including mental health
care providers, and/or the use of medicines or alternative
therapies. A systematic review of the literature found that
cancer patients with fulﬁlled information need experience
less anxiety and depression [27]. Very few studies have
assessed the frequency of use of these strategies to assist
women coping with their worry [28], and even fewer have
examined if provider characteristics or the practice setting
inﬂuences the kinds of resources employed.
How conﬁdent cancer care providers are in presenting
risk information, inquiring about worry about recurrence
and suggesting strategies to manage worry, or the extent
to which there is variation across provider type has not
received sufﬁcient research attention. Both surgeons and
medical oncologists routinely present risk information
during the treatment decision-making phase and provide
ongoing follow-up care to women with breast cancer. A
positive relationship between physician conﬁdence and
competence has been demonstrated in previous studies
[29,30]. For example, in a nationally representative survey
of primary care physicians and medical oncologists, phy-
sicians with greater conﬁdence in their knowledge about
possible adverse psychosocial outcomes were more likely
to engage in psychosocial care of their patients [30]. A
greater understanding of physicians’ attitudes and behav-
iors regarding worry about recurrence in breast cancer
could help women make informed treatment decisions
rather than decisions based on unfounded fears. In addi-
tion, knowing how physicians’ approach to managing
worry about recurrence during the survivorship period
could lead to greater understanding of common ap-
proaches employed, areas where additional training or
skill building may be helpful, and system and resource
barriers that may inhibit providing coordinated quality
cancer care to women in the survivorship period.
To address these gaps in the literature, we evaluated
physicians’ self-reported conﬁdence in presenting risk
information as well as in identifying women with high
levels of worry and managing worry about recurrence in
a randomly selected sample of medical oncologists and
surgeons caring for women with breast cancer. We paid
particular attention to whether these factors differed by
specialty. We further sought to identify the frequency with
which these providers utilize various potential strategies
for managing worry about recurrence, as well as provider
characteristics that correspond with use of different man-
agement approaches.
Methods
Sampling and data collection
Our sample was drawn from the American Medical
Association Physician Masterﬁle (MF), a reasonably
comprehensive list of US physicians, amassed on the basis
of medical school and residency enrollment and licensing
records. We obtained a randomly selected sample of
physicians whose specialty was medical oncology or
hematology/oncology, or surgery or surgical oncology,
along with their contact information. Prior to survey mail-
ing, we telephoned to conﬁrm addresses and to eliminate
subjects whose practices clearly excluded breast cancer.
We originally randomly sampled 750 surgeons and medi-
cal oncologists from the MF. We then called practice to
conﬁrm treatment of breast cancer patients. Those not
treating breast cancer patients were excluded. Afterward,
another random sample was selected from the MF list
equal to the number excluded. The process iterated such that
three different random samples were chosen until we
reached 750 mailed per group that we reasonably believed
at the time of mailing treated breast cancer patients.
Between January and June 2012, we mailed 750
surgeons and 750 medical oncologists a questionnaire
and a $50 cash incentive. We utilized a modiﬁed Dillman
approach, including follow-up with nonresponders, to
maximize response rate [31]. The survey asked potential
participants whether they had seen at least one new breast
cancer patient in the preceding year. If not, they were
asked to return the uncompleted survey. Data were anon-
ymously entered into a RedCap database and exported to
the SAS System, version 9.2 (Cary, NC, USA) for analysis.
This study was approved by the University of Michigan
Institutional Review Board.
Measures
The questionnaire was developed after a literature review
and search for existing measures where available. Next,
we employed an iterative design process and standard
techniques of content validation, including systematic
review of questions by content matter experts and experts
in survey design. Instrument reﬁnement also included
cognitive pre-testing with surgeons and medical oncolo-
gists outside our target sample.
593Presenting risk of recurrence and managing worry in cancer survivors
Copyright © 2014 John Wiley & Sons, Ltd. Psycho-Oncology 24: 592–600 (2015)
DOI: 10.1002/pon
Dependent measures
Conﬁdence in presenting risk information, identifying
women with high levels of worry, and managing
worries about recurrence: Clinician conﬁdence in their
ability to (a) present risk information to a breast cancer
survivor in a way they will understand, (b) identify breast
cancer survivors with high levels of worry, and (c) help
breast cancer survivors manage their worries surrounding
recurrence was assessed on 5-point Likert-type scales with
endpoints labeled ‘not at all conﬁdent’ and ‘extremely
conﬁdent.’ For purposes of analysis, we collapsed the
responses into two categories: <4 was considered ‘not
conﬁdent’, and ≥4 was considered ‘conﬁdent’.
Initiate discussions on worry: Respondents were asked
whether they routinely initiated discussions regarding
worry about recurrence with the breast cancer patients
who did not bring up the issue themselves (yes/no).
Strategies used to manage worry:We inquired about the
likelihood that physicians would use nine different strate-
gies if their patient appeared very worried about the likeli-
hood of her cancer returning. The strategies included
‘address her concerns in detail yourself’, ‘encourage her
to join a cancer support group’, ‘schedule follow-up visits
more frequently’, and ‘prescribe medications’, among
others (Table 2). Responses were on a 4-point Likert-type
scale ranging from ‘deﬁnitely no’ to ‘deﬁnitely yes’. For
purposes of analysis, we collapsed the response options
into two categories: ‘deﬁnitely no’ and ‘probably no’ were
collapsed into ‘no’, and ‘probably yes’ and ‘deﬁnitely yes’
were collapsed into ‘yes’.
Independent measures
Provider and practice characteristics: Provider charac-
teristics assessed included gender (male/female), race/
ethnicity (White/Caucasian, Black/African American,
Hispanic/Latino, Arab or Arab American, American
Indian or Alaska Native, Asian or Paciﬁc Islander, and
other; collapsed during analysis to White, Asian or Paciﬁc
Islander, other), age, and years since completing
residency. Practice characteristics included whether the
practice includes residents or fellows (yes/no), whether
the practice arranged same-day appointment with other
clinicians/specialists (yes/no), number of newly diagnosed
women seen in the past year (≤10, 11–20, 21–50, ≥51).
Clinicians also were asked to indicate the percentage of
early stage breast cancer patients they followed for: (a)
no more than 1 year, (b) between 1 and 3 years, (c) more
than 3 years, or (d) more than 5 years after completion of
therapy (collapsed during analysis into ≤3 years vs
>3 years).
Analysis plan
We described the study sample by demographic and prac-
tice characteristics and then generated descriptive statistics
for the three groups of variables of interest: providers’
conﬁdence in presenting risk information, their assessment
of their patients’ understanding of their recurrence risk, and
the providers’ strategies to help their patients’ manage
worry about recurrence. We tested for the signiﬁcance of
observed differences between surgeons and medical oncol-
ogists using the chi-square statistic and Student’s t-test for
categorical and continuous data, respectively.
We further developed multiple variable logistic regres-
sion models to explain conﬁdence in presenting risk,
assessing and managing worry, and the odds of using the
nine strategies for the management of worry about
recurrence (yes/no). For example, the probability of use
of each strategy was modeled separately with the provider
specialty (oncologist or surgeon) as the primary indepen-
dent variable after controlling for provider gender, time
in practice, patient volume, having residents or fellows,
whether same-day appointments are scheduled for patients
with other breast cancer specialists, and the duration of
clinical follow-up for patients. Full models that included
all covariates simultaneously are reported. For all statisti-
cal tests, p-values ≤0.05 were considered signiﬁcant.
Results
We received a total of 896 responses, a 60.5% response rate
after adjusting for 17 surveys returned because of invalid
addresses and two physicians who had retired. Of the
respondents, 130 reported that they did not see any new
breast cancer patients in the last 12 months. The remaining
766 respondents constituted our analytical sample: 403
surgeons and 363 medical oncologists. Table 1 displays
the physician demographic and practice setting characteris-
tics. The majority of the sample was male (79.2%) and
White (73.6%). The mean age was 52 years. A greater
proportion of surgeons compared with medical oncologists
were male (85.0% vs 72.7%; p-value< 0.001), White
(81.0% vs 65.3%; p-value> 0.001), and older (53 years
compared with 51 years, p=0.014).
About a quarter of those surveyed saw less than 10 newly
diagnosed patients in the past year, with another 50% who
saw between 11 and 50 patients, and slightly less than a
quarter who saw more than 50 newly diagnosed patients
in the past year. Signiﬁcant differences by provider type
were noted with 16% of surgeons versus 30% of medical
oncologists reported seeing more than 50 new breast cancer
patients within the past 12 months (p< 0.001). Most of the
survey respondents (74.8%) reported following the majority
of their patients for 3 years or more compared with 25.2%
who reported seeing patients for less than 3 years. Approx-
imately, 56% of surgeons reported following the majority of
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their patients greater than 3 years compared with over 90%
of medical oncologists (p< 0.001).
Figure 1 displays the percent of respondents who indi-
cated that they were conﬁdent in presenting risk information,
identifying women who were worried about recurrence, and
managing patients’ worry. Overall, both surgeons and med-
ical oncologists more often reported having conﬁdence in
presenting risk, followed by identifying women who have
worry, and then helping women manage worry about recur-
rence. Medical oncologists were signiﬁcantly more likely to
report conﬁdence in presenting risk information compared
with surgeons (87.5% and 73.2%, p< 0.001). About 74%
of medical oncologists reported being conﬁdent in identify-
ing women who are worried compared with approximately
64% of surgeons (74.1% vs 63.9%, p=0.002). A similar pat-
tern was seen with physician conﬁdence in managing worry.
Approximately, 67% of medical oncologists were conﬁdent
in their ability to manage worry compared with just over
50% of surgeons (66.9% vs 52.4%, p< 0.001).
About 60% of respondents reported routinely initiating
discussions regarding worry about recurrence with their pa-
tients who themselves do not bring up the issue, with no sta-
tistically signiﬁcant differences found between provider
type. A signiﬁcant association was found between those
who regularly initiated discussions and their conﬁdence in
their ability to manage worry (p=0.009). About 62% of
those reporting they routinely initiate discussion regarding
worry about recurrence reported conﬁdence in their ability
to help breast cancer survivors manage worry, whereas only
about 53% who do not routinely inquire about worry
reported being conﬁdent about managing worry.
When we modeled the three domains of conﬁdence
(i.e., presenting risk information, identifying survivors
with high levels of worry, and managing worry about
recurrence) by provider and practice characteristics, there
were a number of signiﬁcant relationships that emerged.
Medical oncologists were more likely than surgeons to
report conﬁdence in presenting risk information (odds
ratio (OR) = 1.92, 95% CI 1.25–2.99) and in managing
survivors worry about recurrence (OR= 1.66, 95% CI
1.18–2.34). Across clinician characteristics, female com-
pared with male physicians were more likely to report
conﬁdence in identifying survivors with high levels of
worry (OR=2.71, 95% CI 1.67–4.57). Among practice
characteristics, providers with larger patient volumes (i.e.,
having seen greater than 20 breast cancer patients in the last
12 months vs 20 or less such patients) were more likely to
report conﬁdence in presenting risk information (OR=1.92,
95% CI 1.28–2.89) and in identifying survivors with high
levels of worry (OR 1.92, 95% CI 1.36–2.72). Finally, pro-
viders in practices that offer same-day appointments with
different specialists versus those practices who do not were
more likely to report conﬁdence in managing women’s
worry about recurrence (OR=1.76, 95% CI 1.28–2.41).
No signiﬁcant relationships were found between reported
conﬁdence across the three domains and provider time in
practice, availability of residents and fellows in practice,
or length of clinical follow-up.
Table 1. Provider and practice characteristics
Total Surgeons Medical oncologists p-value
Provider characteristicsa
Gender : N (%) <0.001
Male 598 (79.2) 340 (85.0) 258 (72.7)
Female 157 (20.8) 60 (15.0) 97 (27.3)
Race: N (%) <0.001
White 550 (73.6) 320 (81.0) 230 (65.3)
Asian or Paciﬁc Islander 132 (17.7) 39 (9.8) 93 (26.4)
Other 65 (8.7) 36 (9.1) 29 (8.2)
Age: mean (SD) [min.–max.] 52 (10) [32–76] 53 (9) [32–75] 51 (10) [33–76] 0.014
Years since completing residency: mean (SD) [min.–max.] 19 (10) [1.5–45] 20 (9) [1.5–41] 18 (10) [1.5–45] 0.005
Practice characteristics
Residents or fellows 0.292
Yes 193 (25.3) 108 (26.9) 85 (23.5)
No 570 (74.7) 294 (73.1) 276 (76.5)
Same-day appointments available to meet with clinician specialists 0.672
Yes 340 (44.4) 176 (43.7) 164 (45.2)
No 424 (55.4) 226 (56.1) 198 (54.6)
Number of newly diagnosed patients seen in the last 12 months <0.001
≤10 200 (26.2) 143 (35.6) 57 (15.7)
11–20 167 (21.9) 99 (24.6) 68 (18.8)
21–50 227 (29.7) 97 (24.1) 130 (35.9)
>50 170 (22.2) 63 (15.7) 107 (29.6)
Majority of cases followed for >3 years <0.001
No: N (%) 188 (25.2) 165 (42.1) 23 (6.5)
Yes: N (%) 557 (74.8) 227 (57.9) 330 (93.5)
aMissing/not reported data were less than 5% for all characteristics and were omitted from this table. Percentage should total to 100 with the exception due to rounding.
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Figure 2 displays the frequency with which surgeons
and medical oncologists reported that they would use each
of several potential strategies for managing worry about
recurrence, from the most to least frequently used across
both provider types. Overall, the strategies endorsed most
frequently included addressing the concerns themselves
and encouraging the women to join a cancer support
group. Surgeons were more likely than medical oncolo-
gists to recommend joining a support group or offer read-
ing material, whereas medical oncologists were more
likely to suggest alternative therapies, make referrals to a
psychologist or social worker, and prescribe medication.
Table 2 presents the associations when modeling the use
of potential strategies to manage worry by a number of
provider and practice characteristics. Signiﬁcant differences
remained by provider type (surgeon versus medical oncolo-
gist) as seen in Figure 2, even when controlling for all other
provider and practice factors. Other noted differences
included that female (compared with male) physicians were
more likely to report referring women to a psychologist/
social worker and recommending alternative therapies.
Providers who had been in practice longer were less likely
to encourage their patients to get involved in peer coun-
seling and to prescribe medication. Practice characteristics
such as patient volume and the availability of residents
and fellows inﬂuenced the likelihood of using referrals and
alternative therapies. Physicians who reported following
most of their patients longer were more likely to address
patient concerns themselves compared with those who
followed patients for less time.
Discussion
Although addressing worry about recurrence is an impor-
tant need of breast cancer survivors [1–7], little research
has focused on physicians’ behaviors and perspectives
Figure 1. Percent physicians conﬁdent in presenting risk, identifying women with worry, and managing worry about recurrence, by provider type
Figure 2. Strategies used to manage worry about recurrence, by provider type
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regarding assessing and managing women’s concerns
about cancer recurrence [14,15,32]. Our ﬁndings suggest
that most surgeons and medical oncologists feel conﬁdent
presenting risk information, conﬁdence which may or
may not be justiﬁed given the evidence of patient confu-
sion about such communications [21,33]. However, these
same clinicians appear somewhat less conﬁdent in identi-
fying women who are worried and report being the least
conﬁdent in managing patients’ worry about recurrence.
It was somewhat troubling that almost half of the surgeons
in our sample expressed medium/low conﬁdence in their
ability to help women manage their worries about recur-
rence. In addition, we found that when women are identi-
ﬁed who express high levels of worry about recurrence,
the strategies employed to manage their concerns differed
considerably between surgeons and medical oncologists.
Cancer patients want their provider team to ask about and
to help manage their psychosocial concerns, as many pa-
tients may be reluctant to raise emotional distress themselves
unless invited to do so [32,34–36]. Detmar et al. (2000) [32]
found that although 94% of patients wanted to discuss
emotional functioning with their doctors, 39% would do so
only if the physician initiated the discussion. Another factor
that may inﬂuence whether some physicians’ inquire about
worry about recurrence is an assumption that other cancer
providers or health team members are managing these emo-
tional needs [30]. Clearly, discordant expectations about
who is responsible for initiating discussions may contribute
to gaps in survivorship care [37–39].
Routinely assessing all breast cancer survivors about
worry is needed to capture those who exhibit consider-
able worry despite rather low actual risk of recurrence
[2,40–42]. Our ﬁndings suggest that about 40% of physi-
cians surveyed do not routinely inquire about worry, and
those with less conﬁdence in managing worry were less
likely to report routine assessments. These represent missed
clinical opportunities to assess the psychosocial needs of
cancer survivors and provide appropriate supportive care
for those in need. In addition, physicians frequently fail to
detect their patients’ distress accurately [16,43–45], most
often under-estimating the level of distress [46]. Focused
seminars, online webinars, and/or training opportunities
are needed to raise the level of conﬁdence among some
cancer providers in assessing worry [30]. Surgeons and
providers seeing fewer breast cancer patients in their prac-
tice may beneﬁt from targeted skills training.
Providers also may ﬁnd the use of validated measures to
assess worry about recurrence beneﬁcial. A recent review of
distress screening tools in cancer concluded that few have
been compared with one another but that use of tools seems
to improve communication between patients and providers
and may enhance psychosocial referrals [47]. In one study
where oncologists were provided with a summary of
patients’ quality-of-life assessments before a consultation,
patients received more counseling on how to manageT
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problems [32]. Validated measures assessing worry need to
provide guidelines for interpretation of clinically meaning-
ful scores that indicate the need for intervention, such as
referral to a mental health professional [8]. The current tools
for evaluating fears about cancer recurrence are under-
utilized. A systematic review identiﬁed a total of 20 relevant
multi-dimensional instruments measuring fear of cancer re-
currence, 10 of which were brief measures (containing be-
tween 2 and 10 items) that would be suitable for use in a
clinical setting [48]. Additionally, several of these brief
measures were developed speciﬁcally for use with breast
cancer patients [49–51]. Further studies should evaluate
the efﬁcacy of using brief measures in the clinical setting
as a means of identifying women with enhanced worry in
need of supportive care.
Managing worry about recurrence may require a coordi-
nated approach that enlists the services of multiple care
providers and employs a variety of strategies tailored to
the setting and the need of the individual patient. Although
we found that the use of strategies differed primarily by pro-
vider type, some characteristics of the practice setting such
as volume, availability of residents/fellows, and/or same-
day appointments for patients can inﬂuence the supportive
services offered. As expected, providers that followed their
patients longer had more opportunities to monitor worry
and were more likely to endorse addressing a woman’s
worry about recurrence concerns in detail themselves. Over
90% of medical oncologists followed their patients more
than 3 years, but we found differences by specialty even
on multivariable analysis that controlled for duration of
follow-up, so we believe these differences in addressing
worry merit attention. Differences in the nature of training,
normative disciplinary expectations surrounding patient
care and follow-up, and personality types of typical sur-
geons versus oncologists may also be important. For exam-
ple, medical oncologists may be more comfortable with
both patient counseling and pharmacologic interventions
than surgeons. Greater understanding of the inﬂuence of
physicians’ personal qualities, goals, and/or external cir-
cumstances that can impact interactions with cancer
patients is needed [36,52]. In addition, more empirical stud-
ies are needed to assess the relative beneﬁt of interventions
to reduce worry and in what circumstances one strategy
may be more beneﬁcial than another (online versus cogni-
tive behavioral approaches versus support groups) [8,53].
Our study has a number of strengths, including a rela-
tively high response rate from a national sample of medical
oncologists and surgeons who were selected solely on the
basis of having seen at least one new breast cancer case in
the preceding year. Limitations include self-report about
conﬁdence and that behavior reported could be subject to
bias relating to recall, or social desirability. In addition, the
nine strategies assessed for managing worry about recur-
rence were not exhaustive and, for example, did not capture
referrals to mental health professionals such as a nurse prac-
titioner or psychiatrist. Further studies should focus on a
more in-depth examination of various strategies and referral
patterns and how they may differ by access and health sys-
tem factors. Although not within the scope of this study, it
would be useful to determine if surgeons and oncologists
are aware of resources and support services available at their
institutions or within their communities, and the extent to
which they utilize these resources.
In summary, given the Institute of Medicine’s recognition
that psychosocial care is integral to quality survivorship care
[13] further attention needs to be devoted to assessing psy-
chological well-being, recognizing women in distress, and
managing women with excessive worry about recurrence.
Strategies to manage distress need to be more carefully eval-
uated across diverse populations and time since diagnosis.
Survivorship care plans could provide a vehicle for commu-
nication between care providers and the patient [53]. Models
of care coordination [54] must be developed and assessed to
increase the likelihood that psychological distress such as
worry about recurrence is being recognized and addressed.
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